OTC · EIGRQ
Eiger BioPharmaceuticals, Inc.
$8.50+$0.50 (+6.25%)
Eiger BioPharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 46.88% below the high.
Loading market information…
NASDAQ · SQL · USD
Stock price, earnings
Quote as of Jan 16, 2025, 09:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow SeqLL Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Globally, SeqLL Inc. operates as a life sciences enterprise, providing specialized instrumentation and research services. The company's primary focus involves the innovation, refinement, and production of cutting-edge genetic analysis technologies. Among its key offerings is the proprietary true single molecule sequencing (tSMS) platform, which facilitates the direct sequencing of DNA and RNA at the individual molecular level. SeqLL has established collaborative agreements with a range of esteemed organizations, including Bernstein Laboratory, Ting Laboratory, The Jackson Laboratory for Genomic Medicine, Weizmann Institute of Science, True Bearing Diagnostics, Inc., and Tetracore, Inc. Its diverse clientele encompasses academic institutions, governmental agencies, hospitals and medical centers, pharmaceutical and biotechnology companies, and various non-profit research groups. Established in 2013, the company maintains its headquarters in Billerica, Massachusetts.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 01:59 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
THE ANALYST VIEW
1 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$8.50+$0.50 (+6.25%)
Eiger BioPharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 46.88% below the high.
$1.73-$0.02 (-1.14%)
Vyome Holdings, Inc.’s quoted price sits in the lower half of its reported 52-week range, 73.63% below the high.
$5.01+$0.08 (+1.62%)
Palatin Technologies, Inc.’s quoted price sits in the lower half of its reported 52-week range, 83.84% below the high.
$5.62+$1.35 (+31.62%)
Applied DNA Sciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 98.24% below the high.
$0.09-$0.03 (-24.84%)
Novan, Inc.’s quoted price sits in the lower half of its reported 52-week range, 97.17% below the high.
$0.09$0.00 (0.0%)
PLx Pharma Inc.’s quoted price sits in the lower half of its reported 52-week range, 97.45% below the high.
$0.08-$0.02 (-15.9%)
Aspira Women's Health Inc.’s quoted price sits in the lower half of its reported 52-week range, 97.74% below the high.
$0.25-$0.09 (-27.68%)
Notable Labs, Ltd.’s quoted price sits in the lower half of its reported 52-week range, 94.15% below the high.
